semaglutide .2 Weight loss drug benefits obese patients presenting with HFpEF, type 2 diabetes Personalized Compounded Semaglutide | Alan

Patients should be advised on strategies to manage these symptoms and encouraged to report any persistent or severe gastrointestinal issues to their healthcare provider

Contraindications History of cardiovascular disease (e.g., coronary artery disease, stroke, arrhythmias, congestive heart failure, uncontrolled hypertension) During or within 14 days following the administration of monoamine oxidase inhibitors Hyperthyroidism Glaucoma Agitated states History of drug abuse Pregnancy [see Use in Specific Populations (8.1)] Nursing [see Use in Specific Populations (8.3)] Known hypersensitivity, or idiosyncrasy to the sympathomimetic amines 5

In 3,533 adults with type 2 diabetes and chronic kidney disease, semaglutide 1.0 mg reduced the primary composite kidney outcome by 24%

Month 3 : Dosage moves up to 1.0 mg weekly, further aiding in your health goals